BioSpace News Archive

9 Meters Biopharma, Inc. today announced that the Company’s CEO, John Temperato is scheduled to present at the Cantor Virtual Global Healthcare Conference and invites investors to participate via webcast and in one-on-one meetings.

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today provided a business update and announced that the Nasdaq Stock Market (“Nasdaq”) has confirmed to Acasti that the Company has regained compliance with Nasdaq’s minimum bid price requirement.

Q BioMed Inc. is pleased to provide an update on its partner asset MAN-19 for the treatment of Acute Respiratory Distress Syndrome (ARDS), a condition caused by viral infections in the lungs including COVID-19.

Legend Biotech Corporation will host its first Research & Development Day on Monday, October 18, commencing at 10:00 a.m. (Eastern Time), at Andaz 5th Avenue in New York.

Clover Biopharmaceuticals, Ltd. and CEPI announced that Clover’s adjuvanted protein-based COVID-19 vaccine candidate, SCB-2019 achieved the primary efficacy endpoint and secondary efficacy endpoints in SPECTRA, a global pivotal Phase 2/3 clinical trial.

NuVasive, Inc. announced it will continue its long-standing partnership with the Scoliosis Research Society with a double diamond sponsorship and will attend the society’s 56th Annual Meeting from September 22 to 25, 2021 in St. Louis, Mo.

Codagenix Inc. today announced that their novel intranasal COVI-VAC vaccine has demonstrated promising safety and immunogenicity results in their Phase 1 dose escalation trial in healthy adults.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that it will present new clinical data and attend several renowned international conferences in September and October.

Akoya Biosciences, Inc. (NASDAQ: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the appointment of Myla Lai-Goldman, MD, a true pioneer and leader in the diagnostic industry, to its board of directors.

Erasca, Inc. announced dosing of the first patient in HERKULES-3, a Phase 1b/2 master protocol clinical trial evaluating ERAS-007 in combination with various agents in patients with gastrointestinal cancer, with initial focus on patients with advanced colorectal cancer.